Metagenomi Therapeutics
58 hedge funds and large institutions have $14.2M invested in Metagenomi Therapeutics in 2025 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 12 increasing their positions, 22 reducing their positions, and 19 closing their positions.
37% more capital invested
Capital invested by funds: $10.4M → $14.2M (+$3.79M)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
4.62% less ownership
Funds ownership: 20.61% → 15.99% (-4.6%)
16% less funds holding
Funds holding: 69 → 58 (-11)
45% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 22
53% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 19
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Investments
New York
|
+$393K |
| 2 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$197K |
| 3 |
Walleye Capital
New York
|
+$145K |
| 4 |
JP Morgan Chase
New York
|
+$124K |
| 5 |
Man Group
London,
United Kingdom
|
+$107K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PVI
Pura Vida Investments
New York
|
-$1.4M |
| 2 |
TCM
Tang Capital Management
San Diego,
California
|
-$349K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$194K |
| 4 |
AQR Capital Management
Greenwich,
Connecticut
|
-$191K |
| 5 |
Goldman Sachs
New York
|
-$161K |
MGX Hedge Fund Activity: Q3 2025 in Review
58 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Metagenomi Therapeutics (MGX) for Q3 2025, worth a combined $14.2M — up 37% from $10.4M a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of MGX and 9 opened new positions — a net loss of 10 holders — while 22 trimmed existing stakes and 12 added.
The largest buyer was Two Sigma Investments, adding an estimated $393K. The largest seller was Pura Vida Investments, cutting an estimated $1.4M.
- 58 institutional investors held Metagenomi Therapeutics (MGX) as of Q3 2025, down from 69 in Q2 2025.
- Funds reported $14.2M of Metagenomi Therapeutics stock for Q3 2025, up 37% quarter-over-quarter.
- 9 funds opened new Metagenomi Therapeutics positions in Q3 2025 and 19 closed out, a net change of -10 holders.
- The largest Metagenomi Therapeutics buyer in Q3 2025 was Two Sigma Investments, an estimated $393K added.
- The largest Metagenomi Therapeutics seller in Q3 2025 was Pura Vida Investments, an estimated $1.4M sold.
Based on aggregated 13F filings for Q3 2025.